search
Back to results

The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial) (DIOXXACT)

Primary Purpose

Eye Disease

Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Dorzolamide 20 mg and Timolol 5 mg
Sponsored by
Maisonneuve-Rosemont Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Eye Disease focused on measuring Ocular Hypertension, Open Angle Glaucoma

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjets with open angle glaucoma or ocular hypertension currently on latanoprost immunotherapy.
  • Subjets must have clear media, corrected visual acuity of 6/12 or better,and be able to sit for imaging.

Exclusion Criteria:

  • Subjets with contraindications or known allergies to any of the components of Cosopt.
  • Subjets who had undergoing laser or any ocular surgery.

Sites / Locations

  • Maisonneuve-Rosemont Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cosopt

Arm Description

Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone

Outcomes

Primary Outcome Measures

Clinical evidence for lower diurnal variational Intraocular Pressure

Secondary Outcome Measures

The Intraocular Pressure, Retinal and choroidal blood flow will be stabilized on Cosopt therapy

Full Information

First Posted
August 4, 2009
Last Updated
March 23, 2017
Sponsor
Maisonneuve-Rosemont Hospital
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00957190
Brief Title
The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)
Acronym
DIOXXACT
Official Title
Change in Optic Nerve Head Blood Flow,Optic Nerve Topography and Diurnal Fluctuation of Intraocular Pressure and Pulsatile Ocular Blood Flow in Glaucoma:Cosopt and Xalatan vs Xalatan Alone
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
May 4, 2009 (Actual)
Primary Completion Date
September 14, 2011 (Actual)
Study Completion Date
February 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maisonneuve-Rosemont Hospital
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Diurnal and intervisit fluctuations in IOP are strongly associated with progression of open angle glaucoma and therefore need to be minimized. Control of diurnal fluctuations of IOP with different ocular hypotensive medications has been studied in some detail. But how do IOP changes contribute to progressive glaucomatous optic nerve damage? It is reasonable to assume that there are two principal effects of IOP changes. First, IOP fluctuations result in changes in the stresses and strains on the ONH which in turn result in morphological changes to the ONH. These morphological changes could in turn result in stretching and damage to axons of the ONH. Secondly, IOP fluctuations results in changes to the forces acting on the ONH vasculature, leading to changes in ONH vascular perfusion. These changes to perfusion could in turn result in relative ischemia of the ONH and consequent ONH damage. The investigators propose to monitor diurnal fluctuations in IOP and choroidal blood flow (Pulsatile Ocular Blood Flow,POBF), and intervisit ONH topographical and blood flow changes-ie to monitor the direct ONH consequences of IOP . Open angle glaucoma patients are commonly prescribed topical latanoprost as first line therapy. The EXACCT study, for which I was the principal investigator and which is now submitted for publication, demonstrated that COSOPT was an efficacious choice as second line therapy for patients not controlled on latanoprost monotherapy. The investigators will therefore recruit 20 OAG patients on latanoprost monotherapy, perform diurnal curves of IOP, as well as a.m. ONH morphology and ONH blood flow. Cosopt will then be added and at the next visit the same measurements will be repeated. The investigators expect that when Cosopt is added the investigators will demonstrate improved IOP, morphology and blood flow compared to the latanoprost baseline. Furthermore the investigators expect the the diurnal fluctuation of IOP and choroidal blood flow will be stabilized on Cosopt therapy. The implications are that adding Cosopt to latanoprost can stabilize not only the IOP but also the damaging consequences of IOP to the optic nerve head.
Detailed Description
Twenty patients with open angle glaucoma or ocular hypertension currently on latanoprost immunotherapy will be recruited. A complete routine ophthalmic examination including biomicroscopy, gonioscopy and fundus ophthalmoscopy will be performed. The eye with better visual acuity is selected for fundus flowmetry. All patients will undergo a complete diurnal workup including IOP, as well as 10am Confocal scanning laser ophthalmoscopy (Heidelberg Retina Tomography-3) of ONH topography. Optic nerve head, nasal and temporal peripapillary retinal blood flow are measured with scanning laser Doppler flowmetry (SLDF; Heidelberg Retinal Flowmeter/Tomograph, SLDF analysis software v3.3, Heidelberg Engineering, Germany Goldmann IOP will be measured at 8am, 10am 2pm and 4pm. Pulse amplitude, similar to Pulsatility Ocular Blood Flow (POBF) will be measured using the Pascal Dynamic Contour Tonometer (DCT) at 8am, 10am, 2pm, and 4 pm. All procedures will conform to the Declaration of Helsinki and the study will be approved by the Ethics Committee and each patient will sign an informed consent form. Following visit one, Cosopt will be added to the patients therapy (bid). Following 6 weeks of therapy patients will return for visit two. Cosopt will be applied by the investigator at 8am on visit 2. We expect that this blood flow will be improved with COSOPT therapy and that the diurnal fluctuation of this parameter will be improved as well. It is evidently of great interest to examine diurnal changes in ocular blood flow with and without COSOPT and the measurement of POBF can be performed without great cost and is well tolerated by the patient. Changes in IOP, ONH Topography, and ONH blood flow will be analysed using appropriate statistical approaches

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Eye Disease
Keywords
Ocular Hypertension, Open Angle Glaucoma

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cosopt
Arm Type
Experimental
Arm Description
Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
Intervention Type
Drug
Intervention Name(s)
Dorzolamide 20 mg and Timolol 5 mg
Other Intervention Name(s)
Cosopt
Intervention Description
Twice daily in the affected eye(s)
Primary Outcome Measure Information:
Title
Clinical evidence for lower diurnal variational Intraocular Pressure
Time Frame
Six weeks
Secondary Outcome Measure Information:
Title
The Intraocular Pressure, Retinal and choroidal blood flow will be stabilized on Cosopt therapy
Time Frame
Six weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjets with open angle glaucoma or ocular hypertension currently on latanoprost immunotherapy. Subjets must have clear media, corrected visual acuity of 6/12 or better,and be able to sit for imaging. Exclusion Criteria: Subjets with contraindications or known allergies to any of the components of Cosopt. Subjets who had undergoing laser or any ocular surgery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark R Lesk, MSc,MD
Organizational Affiliation
Maisonneuve-Rosemont Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maisonneuve-Rosemont Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
14509472
Citation
Hafez AS, Bizzarro RL, Rivard M, Trabut I, Lovasik JV, Kergoat H, Lesk MR. Reproducibility of retinal and optic nerve head perfusion measurements using scanning laser Doppler flowmetry. Ophthalmic Surg Lasers Imaging. 2003 Sep-Oct;34(5):422-32.
Results Reference
result
PubMed Identifier
12614754
Citation
Yoshida A, Feke GT, Mori F, Nagaoka T, Fujio N, Ogasawara H, Konno S, Mcmeel JW. Reproducibility and clinical application of a newly developed stabilized retinal laser Doppler instrument. Am J Ophthalmol. 2003 Mar;135(3):356-61. doi: 10.1016/s0002-9394(02)01949-9. Erratum In: Am J Ophthalmol. 2003 Aug;136(2):following 403.
Results Reference
result
PubMed Identifier
17102003
Citation
Lesk MR, Hafez AS, Descovich D. Relationship between central corneal thickness and changes of optic nerve head topography and blood flow after intraocular pressure reduction in open-angle glaucoma and ocular hypertension. Arch Ophthalmol. 2006 Nov;124(11):1568-72. doi: 10.1001/archopht.124.11.1568.
Results Reference
result
PubMed Identifier
8562550
Citation
Michelson G, Schmauss B. Two dimensional mapping of the perfusion of the retina and optic nerve head. Br J Ophthalmol. 1995 Dec;79(12):1126-32. doi: 10.1136/bjo.79.12.1126.
Results Reference
result
PubMed Identifier
16303952
Citation
Sehi M, Flanagan JG, Zeng L, Cook RJ, Trope GE. Anterior optic nerve capillary blood flow response to diurnal variation of mean ocular perfusion pressure in early untreated primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4581-7. doi: 10.1167/iovs.05-0209.
Results Reference
result

Learn more about this trial

The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)

We'll reach out to this number within 24 hrs